Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticarial

NCT02012387 is registered in ClinicalTrials.gov with Clinica Universidad de Navarra, Universidad de Navarra as lead sponsor.

NCT NCT02012387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02012387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticarial
Lead sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2014
Completion date
June 30, 2017
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholinergic urticaria